Dose Escalation Study With Bispecific Antibodies in Adult Participants With Lupus Nephritis | MicrobiomeTrials← Back to trialsNCT06975787
Dose Escalation Study With Bispecific Antibodies in Adult Participants With Lupus Nephritis
RecruitingPHASE1INTERVENTIONAL
Trial Details
Start: 2025-12-22Est. Completion: 2029-09-09
Enrollment target: 90 participants Locations- Mayo Clinic, Rochester, Minnesota, United States
- Baylor College of Medicine, Houston, Texas, United States
- University Medical Center of the Johannes Gutenberg-University Mainz, Mainz, Germany
- Hallym University Sacred Heart Hospital, Anyang-si, Gyeonggi-do, South Korea
- Seoul National University Hospital, Seoul, South Korea
- Samsung Medical Center, Seoul, South Korea
- Hospital Regional Universitario de Malaga, Málaga, Spain
- Changhua Christian Hospital, Changhua, Taiwan
- Taichung General Veterans Hospital, Taichung, Taiwan
- National Taiwan University Hospital, Taipei, Taiwan
- Taipei Veterans General Hospital, Taipei, Taiwan
Other microbiome trials you might be interested in
Lupus Erythematosus, Systemic
The study will evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of cevostamab in participants w…
Multiple LocationsEst. completion Mar 29, 2030
Lupus NephritisPrimary Membranous Nephropathy
This is a Phase 1/2, open-label, multi-center, multi-cohort, non-randomized dose escalation and dose expansion basket st…
Little Rock, United StatesEst. completion Apr 2027